Amyloid PET using 18F-florbetapir (Amyvid) is an established radiotracer of amyloid-β pathology and neuronal injury in Alzheimer’s disease.

Alzheimer’s disease (AD) is the most common form of dementia, that causes problems with memory, thinking, and behavior accounting for 50 to 60% of all cases. Diagnosis of AD is hampered by the lack of noninvasive biomarkers of the underlying pathology. Clinicians may not diagnose AD in 33% of patients with mild signs and symptoms. Thus, a diagnostic biomarker may help physicians separate patients who have AD pathology from those who do not.

Learn more:

Vizamyl PET/CT 

Amyvid PET/CT